BioVie Inc. (BIVI) stock is down significantly after announcing mixed topline results from its Phase 2 ADDRESS-LC study for Long COVID. While the full intent-to-treat population did not show statistical significance, pre-specified subgroup analyses revealed significant improvements in patients with higher baseline symptom burden, leading to investor uncertainty.
BioVie announced topline results from its Phase 2 ADDRESS-LC study for bezisterim in Long COVID patients. The primary issue driving the stock decline is that the full intent-to-treat population did not achieve statistical significance across most endpoints, despite numerical trends favoring the drug. However, pre-specified subgroup analyses showed statistically significant improvements in patients with greater baseline symptom burden, suggesting potential efficacy in a targeted population. This mixed outcome creates uncertainty for investors, leading to short-term bearish pressure on BIVI shares as the market digests the nuances of the trial data and awaits confirmation in future studies. The positive safety profile and ongoing Parkinson's program offer some long-term potential, but the immediate focus is on the Long COVID results.